Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment

NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation.Alzheimer's Disease Agitation DataIn the Phase 1b study, NMRA-511 showed a favorable safety profile with no somnolence or sedation, and meaningful improvements in agitation. Patients saw placebo-adjusted CMAI total score changes of -2.6 and -2.1 at Weeks 6 and 8, while those with elevated anxiety improved by -7.6 and -5.6, respectively.William Blair projects peak U.S. sales of $1.8 billion for NMRA-511 and called the early ...